REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

REGENXBIO Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Delivery

January 10, 2022

ROCKVILLE, Md., Jan. 10, 2022 /PRNewswire/ —

  • ASCENTTM, a Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada
  • Pivotal trials expected to support BLA submission for RGX-314 in 2024

REGENXBIO Inc. (Nasdaq: RGNX) today announced the initiation of ASCENTTM, the second of two Phase III pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (wet AMD). ASCENT, the first trial to be initiated by REGENXBIO under the eye care collaboration with AbbVie, is currently active and screening patients. RGX-314 is being investigated as a potential  one-time gene therapy for the treatment of wet AMD. ...  Read more

MCEDC Business Resource Guide – Updated in English and Spanish

MCEDC Business Resource Guide – Updated in English and Spanish

Looking for government contracting opportunities or access to funding? How about industry-specific resources; diversity, equity and inclusion resources; or additional support at federal, state and local levels? Find it all here in the Montgomery County Economic Development (MCEDC) 21-page, resource-rich guide – newly updated in both English and Spanish. ...  Read more

Governor Hogan Announces $4.6 Billion Tax Relief Package for Hardworking Maryland Families, Small Businesses, and Retirees

Governor Hogan Announces $4.6 Billion Tax Relief Package for Hardworking Maryland Families, Small Businesses, and Retirees

Largest Tax Relief Package In State History, Includes Eliminating 100% of State Retirement Taxes
Additional $650 Million in Tax Relief for Working Marylanders
More Jobs For Marylanders Act 3.0 to Extend Successful, Job Creating Program Through 2027 ...  Read more

Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability

Horizon Therapeutics plc Announces Significant Expansion of East Coast Research and Development and Technical Operations Capability

DUBLIN–(BUSINESS WIRE)–Jan. 6, 2022– Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. to be the first tenant at the Alexandria Center® at Traville Gateway campus in Rockville, Maryland. When completed, the state-of-the-art facility will serve as the company’s primary East Coast research and development and technical operations hub. Construction at the 192,000-square-foot site is underway and Horizon expects to start work on interior improvements in 2023. Additional terms of the agreement were not disclosed. ...  Read more